SynthesisFrontiers in oncology2026
Research hotspots and trends in therapeutic drug monitoring of anticancer drugs: a 1990-2024 bibliometric analysis.
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To explore the current status of therapeutic drug monitoring (TDM) research on anticancer drugs, analyze research hotspots and trends, and provide insights and references for future studies. Methods: Data were retrieved from the Web of Science Core Collection (1990-2024) using keywords related to "anticancer drugs" and "therapeutic drug monitoring." Bibliometric analyses were performed using VOSviewer, CiteSpace, R, and Scimago Graphica to visualize trends in publications, keywords, collaborations, and citation networks. Results: A total of 1474 articles were included. Global research output on TDM for anticancer drugs has grown steadily, with an accelerating trend in recent years. Key research themes include drug-specific monitoring, analytical methodologies, and clinical safety and efficacy. Busulfan remains the most studied agent in hematologic malignancies, while tyrosine kinase inhibitors, particularly crizotinib and nilotinib, along with monoclonal antibodies, have emerged as focal points of recent citation bursts. The keyword "pediatric patients" also shows a strong burst signal, reflecting growing attention to developmental pharmacokinetics and individualized dosing in vulnerable populations. The majority of influential studies were published in clinical oncology and pharmacology journals, with chemotherapy and targeted therapy dominating among the most cited papers. The United States, China, Japan, and Western European countries, notably the Netherlands and France, account for the majority of global publications. Among these, the Netherlands, Switzerland, and France demonstrate not only the highest research intensity, as measured by the Relative Importance Index (RII), but also a gradual increase in RII over time. Institutional-level RII analysis further highlights sustained contributions from leading European academic and clinical networks. International collaboration is highly concentrated among these high-output regions, forming a tightly interconnected research network. Conclusion: This study maps the evolving landscape of TDM in oncology. Accelerating research on tyrosine kinase inhibitors, monoclonal antibodies, and pediatric populations highlights TDM's clinical value in optimizing therapy for narrow-therapeutic-index drugs. Rising research intensity in Europe and strong international collaboration underscore a coordinated global effort, supporting TDM's integration into precision oncology, especially for vulnerable patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.